title: Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected].
abstract: The efficacy and tolerability of mifepristone in combination with misoprostol for termination of early pregnancy (up to 49 days of amenorrhea) are established. We studied the efficacy and tolerability of this combination therapy for termination of pregnancy in women up to 63 days of amenorrhea. We also examined the effect of an additional dose of misoprostol in cases of nonexpulsion within 3 hours after the first dose. The multicenter trial included 1,108 women, mean age 27.9 +/- 6.2 years. The mean duration of pregnancy was 51.7 +/- 9.2 days. On day 1, the women received an oral dose of mifepristone, 600 mg. On day 3, they received an oral dose of misoprostol, 400 micrograms, and were monitored for up to 3 hours. If they did not expel the conceptus within 3 hours, an additional dose of 200 micrograms of misoprostol was given and they were monitored for 2 more hours. From days 10 to 18, the women were followed up with clinical examination, human chorionic gonadotropin measurement, or ultrasound examination. Overall, the procedure was successful in 92.9% of women. Efficacy decreased with the duration of pregnancy, especially after 56 days of amenorrhea. Up to 42 days of amenorrhea, the success rate was 97.6%; between days 42 and 49, 94.8%; between days 50 and 56, 93.4%; between days 57 and 63, 86.8%; and after day 63, 83.3%. The most common side effects were moderate uterine cramps (80.5%) and gastrointestinal (GI) symptoms (34.9%), especially vomiting (18.3%) and diarrhea (10.5%). GI symptoms were generally mild. A second dose of misoprostol was given to 61.6% of the women. In a subgroup analysis, we assessed the efficacy of 600 mg of mifepristone plus 400 or 600 micrograms of misoprostol (one or two doses) in women with up to 49 days of amenorrhea and compared it with the efficacy in women who received mifepristone plus only 400 micrograms (one dose) of misoprostol in a previous study. The overall rate of success (termination of pregnancy) was 95.5% in the current study compared with 95.4% in the previous study. The additional dose of misoprostol did not significantly increase the overall rate of success, but did increase the rate of termination within the monitoring period (69.7% versus 64.9% (and within 72 hours after administration of mifepristone (92.7% versus 90.4%). We have confirmed that the combination of mifepristone and misoprostol was effective, safe, and well tolerated for termination of pregnancies at 49 or fewer days of amenorrhea. The efficacy decreased slightly between 49 and 56 days, and then decreased significantly between 56 and 63 days. For maximal safety and tolerability, we recommend this method only for women with 49 or fewer days of amenorrhea. A second dose of misoprostol did not improve overall efficacy, but did increase the rate of early termination.
authors.affiliation: Centre d'Orthogénie de l'Hôpital Broussais, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Aubény
authors.forename: R
authors.initials: R
authors.lastname: Peyron
authors.forename: C L
authors.initials: CL
authors.lastname: Turpin
authors.forename: M
authors.initials: M
authors.lastname: Renault
authors.forename: V
authors.initials: V
authors.lastname: Targosz
authors.forename: L
authors.initials: L
authors.lastname: Silvestre
authors.forename: A
authors.initials: A
authors.lastname: Ulmann
authors.forename: E E
authors.initials: EE
authors.lastname: Baulieu
mesh_terms: D000019:Abortifacient Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000592:standards; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy* / Q000503:physiopathology; D006063:Chorionic Gonadotropin / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005602:France / Q000453:epidemiology; D006489:Hemostatic Techniques; D006801:Humans; D015994:Incidence; D008600:Menstruation-Inducing Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000592:standards; D015735:Mifepristone / Q000009:adverse effects / Q000494:pharmacology* / Q000592:standards; D016595:Misoprostol / Q000009:adverse effects / Q000494:pharmacology* / Q000592:standards; D011247:Pregnancy / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D011271:Pregnancy, Ectopic / Q000601:surgery; D013997:Time Factors; D014463:Ultrasonography; D014592:Uterine Hemorrhage / Q000139:chemically induced / Q000628:therapy; D014599:Uterus / Q000000981:diagnostic imaging / Q000502:physiology
chemical_list: D000019:Abortifacient Agents; D006063:Chorionic Gonadotropin; D008600:Menstruation-Inducing Agents; D016595:Misoprostol; D015735:Mifepristone